BioCentury | Aug 6, 2007
Company News

HealthLinx, University of Virginia deal

...HTX (formerly Cryptome Pharmaceuticals Ltd. ) and the university expanded an August 2006 deal to give HTX rights...
...for acute respiratory distress syndrome (ARDS) this quarter. Further terms were not disclosed. HTX and Cryptome...
BioCentury | Sep 26, 2005
Company News

Cryptome, University of Virginia deal

...CRP is in-licensing the university's CR014, a peptide that has broad-spectrum activity in vascular leak. Cryptome Pharmaceuticals Ltd....
BioCentury | Jul 11, 2005
Company News

Cryptome, National Trauma Research Institute deal

...preventing or treating inflammatory or traumatic injury of the brain. CRP will own resulting compounds. Cryptome Pharmaceuticals Ltd....
BioCentury | Jun 6, 2005
Company News

Cryptome, Xantos deal

...discovery technology to validate one of Xantos' angiogenic therapeutic leads. CRP is eligible for milestones. Cryptome Pharmaceuticals Ltd....
BioCentury | Apr 18, 2005
Company News

Cryptome, Murdoch Childrens Research Institute deal

...of fragments of the proteins. CRP will have commercialization rights to resulting IP and compounds. Cryptome Pharmaceuticals Ltd....
BioCentury | Apr 18, 2005
Company News

Cryptome, Northeastern University deal

...for identifying and isolating low-abundance human proteins. CRP will have commercialization rights to resulting therapeutics. Cryptome Pharmaceuticals Ltd....
BioCentury | Feb 28, 2005
Company News

Cryptome, University of Virginia deal

...as well as cellular infiltrate in a mouse model of adult respiratory distress syndrome (ARDS). Cryptome Pharmaceuticals Ltd....
BioCentury | Jan 24, 2005
Clinical News

Cryptome preclinical data

...55% delay in clotting at 5 minutes to about a 40% delay at 60 minutes. Cryptome Pharmaceuticals Ltd....
BioCentury | Dec 20, 2004
Company News

Cryptome, University of Queensland deal

...for small protein fragments with therapeutic potential for cardiovascular indications. Financial terms were not disclosed. Cryptome Pharmaceuticals Ltd....
BioCentury | Dec 13, 2004
Company News

Cryptome, University of Queensland deal

...throughput protein fragment discovery platform and the Institute's compound libraries. CRP will screen the libraries. Cryptome Pharmaceuticals Ltd....
Items per page:
1 - 10 of 14
BioCentury | Aug 6, 2007
Company News

HealthLinx, University of Virginia deal

...HTX (formerly Cryptome Pharmaceuticals Ltd. ) and the university expanded an August 2006 deal to give HTX rights...
...for acute respiratory distress syndrome (ARDS) this quarter. Further terms were not disclosed. HTX and Cryptome...
BioCentury | Sep 26, 2005
Company News

Cryptome, University of Virginia deal

...CRP is in-licensing the university's CR014, a peptide that has broad-spectrum activity in vascular leak. Cryptome Pharmaceuticals Ltd....
BioCentury | Jul 11, 2005
Company News

Cryptome, National Trauma Research Institute deal

...preventing or treating inflammatory or traumatic injury of the brain. CRP will own resulting compounds. Cryptome Pharmaceuticals Ltd....
BioCentury | Jun 6, 2005
Company News

Cryptome, Xantos deal

...discovery technology to validate one of Xantos' angiogenic therapeutic leads. CRP is eligible for milestones. Cryptome Pharmaceuticals Ltd....
BioCentury | Apr 18, 2005
Company News

Cryptome, Murdoch Childrens Research Institute deal

...of fragments of the proteins. CRP will have commercialization rights to resulting IP and compounds. Cryptome Pharmaceuticals Ltd....
BioCentury | Apr 18, 2005
Company News

Cryptome, Northeastern University deal

...for identifying and isolating low-abundance human proteins. CRP will have commercialization rights to resulting therapeutics. Cryptome Pharmaceuticals Ltd....
BioCentury | Feb 28, 2005
Company News

Cryptome, University of Virginia deal

...as well as cellular infiltrate in a mouse model of adult respiratory distress syndrome (ARDS). Cryptome Pharmaceuticals Ltd....
BioCentury | Jan 24, 2005
Clinical News

Cryptome preclinical data

...55% delay in clotting at 5 minutes to about a 40% delay at 60 minutes. Cryptome Pharmaceuticals Ltd....
BioCentury | Dec 20, 2004
Company News

Cryptome, University of Queensland deal

...for small protein fragments with therapeutic potential for cardiovascular indications. Financial terms were not disclosed. Cryptome Pharmaceuticals Ltd....
BioCentury | Dec 13, 2004
Company News

Cryptome, University of Queensland deal

...throughput protein fragment discovery platform and the Institute's compound libraries. CRP will screen the libraries. Cryptome Pharmaceuticals Ltd....
Items per page:
1 - 10 of 14